Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. - Wikidata - wikimedia - TriplyDB

Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia.

Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia.

http://www.wikidata.org/entity/Q34752264

about

Mechanisms for the modulation of dopamine d(1) receptor signaling in striatal neurons Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine Phosphodiesterase Inhibition and Regulation of Dopaminergic Frontal and Striatal Functioning: Clinical Implications Identification and Optimization of PDE10A Inhibitors Using Fragment-Based Screening by Nanocalorimetry and X-ray Crystallography Phosphodiesterases as therapeutic targets for Alzheimer's disease.Differential changes in amygdala and frontal cortex Pde10a expression during acute and protracted withdrawal TAK-063, a PDE10A Inhibitor with Balanced Activation of Direct and Indirect Pathways, Provides Potent Antipsychotic-Like Effects in Multiple Paradigms Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating.Phosphodiesterase 10A regulates alcohol and saccharin self-administration in rats Radiosynthesis and in vivo evaluation of [11C]MP-10 as a PET probe for imaging PDE10A in rodent and non-human primate brain Inhibition of Phosphodiesterase 10A Increases the Responsiveness of Striatal Projection Neurons to Cortical Stimulation Effects of a novel phosphodiesterase 10A inhibitor in non-human primates: A therapeutic approach for schizophrenia with improved side effect profile Selective Effects of PDE10A Inhibitors on Striatopallidal Neurons Require Phosphatase Inhibition by DARPP-32(1,2,3)Comparison of [(11)C]TZ1964B and [(18)F]MNI659 for PET imaging brain PDE10A in nonhuman primates Phosphodiesterase 10A Is Tethered to a Synaptic Signaling Complex in Striatum Phosphodiesterase regulation of alcohol drinking in rodents.Review: Modulation of striatal neuron activity by cyclic nucleotide signaling and phosphodiesterase inhibition PDE10A inhibitors stimulate or suppress motor behavior dependent on the relative activation state of the direct and indirect striatal output pathways Phosphodiesterase 10A inhibitor MP-10 effects in primates: comparison with risperidone and mechanistic implications Biallelic Mutations in PDE10A Lead to Loss of Striatal PDE10A and a Hyperkinetic Movement Disorder with Onset in Infancy Cyclic AMP control measured in two compartments in HEK293 cells: phosphodiesterase K(M) is more important than phosphodiesterase localization Genome-wide association study in bipolar patients stratified by co-morbidity Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease Modulation of mGlu2 Receptors, but Not PDE10A Inhibition Normalizes Pharmacologically-Induced Deviance in Auditory Evoked Potentials and Oscillations in Conscious Rats.The prototypical ranitidine analog JWS-USC-75-IX improves information processing and cognitive function in animal models Phosphodiesterase 11A in brain is enriched in ventral hippocampus and deletion causes psychiatric disease-related phenotypes.Neurophysiological biomarkers for drug development in schizophrenia.Effect of chronic antipsychotic treatment on striatal phosphodiesterase 10A levels: a [¹¹C]MP-10 PET rodent imaging study with ex vivo confirmation.Nitric oxide-soluble guanylyl cyclase signaling regulates corticostriatal transmission and short-term synaptic plasticity of striatal projection neurons recorded in vivo Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair.Bioactivities of Compounds from Elephantopus scaber, an Ethnomedicinal Plant from Southwest China.cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.Inhibition of phosphodiesterase10A attenuates morphine-induced conditioned place preference.Schizophrenia drug discovery and development in an evolving era: are new drug targets fulfilling expectations?Discovery of novel PDE10 inhibitors by a robust homogeneous screening assay.Alzheimer's disease and age-related memory decline (preclinical)Synthesis and in vitro characterization of cinnoline and benzimidazole analogues as phosphodiesterase 10A inhibitors.Synthesis and in vitro evaluation of new analogues as inhibitors for phosphodiesterase 10A.Facilitation of corticostriatal transmission following pharmacological inhibition of striatal phosphodiesterase 10A: role of nitric oxide-soluble guanylyl cyclase-cGMP signaling pathways.Characterization of binding and inhibitory properties of TAK-063, a novel phosphodiesterase 10A inhibitor

P2860

Q21131062-10A3EB97-FC16-42A3-BBE0-2167506477A5 Q24649503-3A88D575-1F12-4DAE-92AB-0B1CEBA50320 Q26753116-E39C7B73-A4E3-4996-ACF2-CAFD6E114A10 Q27681131-C7B7359A-0E2C-4B09-9CD9-704EE05E8DB6 Q28279704-E8658A93-A6DF-4AAF-B307-D0D420609F57 Q28383988-7EEAA98E-A4AD-43B6-9491-0949FE685EF0 Q28384192-92E89B49-6766-4167-A811-F524891FE177 Q28385659-8859E8AC-F340-40DE-B38B-D94B65B77D22 Q28386042-4369F25F-D4D6-4ECC-AE4A-D3365B51C11F Q28386823-EA8CB493-99FF-4591-B7AA-6FF9BBB52A7B Q28387521-C1C110A1-4E36-40E5-981F-3B0C7ED22A68 Q28389666-4604B598-E55F-49D6-999D-3D8DC55D41C6 Q28390499-85C3EA5E-184F-4069-BCC2-8C32D55EC3C8 Q28390557-35120D31-ACEB-4AB3-AAE8-4E2FF5488B83 Q28393596-C9F9DED2-DF5D-409D-9214-F068FEE363DF Q28394978-F11294C2-AF88-43CD-9064-DEE17CB03FD6 Q28394979-6D4B55E6-8C38-4D7B-AA15-102A1A47306A Q28395353-621B6B68-B213-47C5-A06C-6D588DD6E4FF Q28396609-E3FBB478-B21D-497F-B9DD-B5B6F1BF4429 Q28592922-58620351-B64A-4140-8F6D-684C20243E92 Q28740548-A03855E1-DC4A-43F5-ADDD-3D77B62A8794 Q28741033-8552F91A-5ED1-4E4D-B4DA-3D95E26036B6 Q28748849-31FF5B85-4804-41EE-880B-A12F29208C1F Q30391868-5CE433C4-531E-4DEB-9C23-86168940F479 Q30470041-00CD7EE8-82B9-4643-A98B-C039634D7D97 Q30478804-F19CBB20-24D7-4D52-B181-1B461C566C70 Q30486447-C9BD820B-2475-400A-8B99-B33999A3D4C3 Q33575007-24F82028-EE69-44C6-847B-5DAB55A8BAB4 Q33618380-30B6BCE9-EFF5-403D-B950-9D7AF807329B Q33624262-9CE74796-DB8E-4D51-9112-03EBB715D98F Q33748655-5B173C0E-F7D7-41AA-A3DB-AE56D907CB6A Q34244951-704F2198-4AA6-4D3C-B70D-F6A851E94735 Q34268331-2FD46AC3-5DAE-4763-B030-4497643BAC3F Q34458090-CB70B4CF-E2A3-4B3D-8BD8-65039DBA3E75 Q34679687-244E6E31-4772-4193-B40A-8511636A0FDC Q35041190-305FDE45-72E2-42BF-8B0A-2BE831498090 Q35063956-AE7AEBCF-C2BC-48CF-94D9-438A9C2D175C Q35190040-DD17C0BE-8EA9-493E-9BEB-217B4877D750 Q35307838-82F2B38E-E745-4E71-A79C-7AE2CD4CE84C Q35588358-2AC57AD2-2349-4A93-8789-18DBFD8B8DE5

P2860

Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia.

http://www.wikidata.org/entity/Q34752264

description

2008 nî lūn-bûn

@nan

2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Preclinical characterization o ...... he treatment of schizophrenia.

@ast

Preclinical characterization o ...... he treatment of schizophrenia.

@en

Preclinical characterization o ...... he treatment of schizophrenia.

@nl

type

label

Preclinical characterization o ...... he treatment of schizophrenia.

@ast

Preclinical characterization o ...... he treatment of schizophrenia.

@en

Preclinical characterization o ...... he treatment of schizophrenia.

@nl

prefLabel

Preclinical characterization o ...... he treatment of schizophrenia.

@ast

Preclinical characterization o ...... he treatment of schizophrenia.

@en

Preclinical characterization o ...... he treatment of schizophrenia.

@nl

P1433

Q34752264-0A1B80FB-DDB2-418C-B46B-C4D31C5ED08D

P1476

Q34752264-46B1BF75-472F-4AB1-AF55-0C9B23369501

P2093

Q34752264-08CBE187-860B-40D4-9236-8C0775DF8858

Q34752264-13269525-AA0E-4D62-A535-09FFEF057A8C

Q34752264-15DEDCE3-2404-401C-8878-6833E26D2AC6

Q34752264-26E6960D-B5C4-488B-836F-4ECB1361069F

Q34752264-3446C4AE-FE54-4A02-AC3B-56E1C9F15117

Q34752264-434E2F7B-1C89-4EFF-BD08-0F4CEFE336F2

Q34752264-4F95FA2E-9ED2-47B3-95EF-E29A237D6807

Q34752264-5F27FCE5-3ECF-4DB3-98C2-E8F6C6AE6F54

Q34752264-625B51F3-34F8-4B61-9F40-EF2C7B90A398

Q34752264-6526E9DB-F1F1-49A7-8ED3-F5CBAA5C4721

P304

Q34752264-100A78A2-9BD3-485F-A714-5C2108824424

P31

Q34752264-44686D44-9089-4900-B6F3-08B434FA7483

P356

Q34752264-2177C528-0DC6-4C41-80D9-801F4150EBF3

P407

Q34752264-E432D0E1-0879-49D2-940B-E3B046ACAA72

P433

Q34752264-5012CE6A-5213-4E21-91FB-5878039C0D62

P478

Q34752264-1A6FAB22-995A-4235-A8CB-DD0AAD5E48C7

P577

Q34752264-9B1FA42C-8D9B-458E-AFE1-9BE63BF1CE81

P5875

Q34752264-739DFB7A-2BFB-42FE-B46C-4CB93CAF6FCB

P698

Q34752264-E817D3B8-A1E1-4F50-8E51-7D8EBA29E0BD

P921

Q34752264-3BC1E3B9-3703-4112-9345-3FEE587F24CB

P356

JPET.107.132910

P1433

Journal of Pharmacology and Experimental Therapeutics

P1476

Preclinical characterization o ...... he treatment of schizophrenia.

@en

P2093

A D Ramirez

http://www.w3.org/2001/XMLSchema#string

C J Schmidt

http://www.w3.org/2001/XMLSchema#string

C Proulx-LaFrance

http://www.w3.org/2001/XMLSchema#string

D S Chapin

http://www.w3.org/2001/XMLSchema#string

F D Tingley

http://www.w3.org/2001/XMLSchema#string

F R Nelson

http://www.w3.org/2001/XMLSchema#string

F S Menniti

http://www.w3.org/2001/XMLSchema#string

J A Siuciak

http://www.w3.org/2001/XMLSchema#string

J Cianfrogna

http://www.w3.org/2001/XMLSchema#string

J F Harms

http://www.w3.org/2001/XMLSchema#string

P304

681-690

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/JPET.107.132910

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

325

http://www.w3.org/2001/XMLSchema#string

P577

2008-02-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5565282

http://www.w3.org/2001/XMLSchema#string

P698

18287214

http://www.w3.org/2001/XMLSchema#string

P921